Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by SPCEO1on Jan 14, 2021 10:31am
151 Views
Post# 32293611

RE:RE:RE:RE:RE:Placement

RE:RE:RE:RE:RE:Placement There are two separate issues going on here. The deal was atrocious based on the timing, pricing and Canadian broker focus. That the company picked up some new institutional investors that might help the company get some new US broker coverage (this is a reach but I am looking for any positive that might come from this debacle as I move through the stages of grief!) is a positive.

 
palinc2000 wrote: They did a bad deal for our own good? That does not make any sense!!!!

SPCEO1 wrote: The way the company views this is they needed to diversify their shareholder base away from us, for our own good. There is likely truth to that. But the way it was done was less than ideal. Hopefully, the new institutional owners will have enough market power with US brokers who are likely to follow THTX to compel them to pick up coverage and we will salvage something from this situation. But TH will need to convince these brokers that their NASH opportunity should be valued at an appropriate discount rather than the current enormous discount if we are going to see any decent analysis coming from any new analyst coverage. If we get more of the same that we have already seen, there is no point to getting new analysts to cover the stock. Sadly, the deal is a big hurdle to getting the appropriate price for the stock since if the company agrees this is a fair price, why would any analyst stick their head out and suggest the stock price should be at say 60% of MDGL's or NGM's level? 

1998novl wrote: So if nobody on this board bought any additional shares than our representation just dropped by 32%! From 30% down to 20%! Our voice is not as strong as it once was. 

 




<< Previous
Bullboard Posts
Next >>